Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL... Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. Mehr anzeigen
CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 5.5795 | 1.84227035594 | 302.86 | 315.09 | 289.8 | 377085 | 300.74026151 | CS |
| 4 | -20.8105 | -6.3205770691 | 329.25 | 351.805 | 289.8 | 333344 | 318.02976149 | CS |
| 12 | 92.3395 | 42.7299861175 | 216.1 | 368.29 | 200.63 | 428256 | 288.25057473 | CS |
| 26 | 35.0595 | 12.8244568001 | 273.38 | 368.29 | 200.63 | 349137 | 275.82297279 | CS |
| 52 | 78.6395 | 34.2208442124 | 229.8 | 368.29 | 168.2462 | 428360 | 251.84105562 | CS |
| 156 | 231.4395 | 300.570779221 | 77 | 368.29 | 52.33 | 372963 | 204.48571006 | CS |
| 260 | 219.1795 | 245.551758907 | 89.26 | 368.29 | 52.33 | 284580 | 181.91970739 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
